Payment overview · 2025
General Payments
$2,382.33
121 reported records · 28 companies
Healthcare provider profile · identity verified
Michael Neshewat, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHGATE, MI · NPI 1174553770
Verified facts
What the public records show
CMS Open Payments records show Michael Neshewat, M.D. received $2,382.33 in general payments during 2025 across 121 reported records.
ABBVIE INC. accounted for 12.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $284.97 | 12.0% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $274.68 | 11.5% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $262.97 | 11.0% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $233.32 | 9.8% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $148.04 | 6.2% | 8 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $143.42 | 6.0% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $135.26 | 5.7% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $94.57 | 4.0% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.89 | 3.0% | 4 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.51 | 3.0% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $67.62 | 2.8% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $67.52 | 2.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.42 | 2.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.27 | 1.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.11 | 1.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.94 | 1.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.70 | 1.6% | 2 | 2025 |
| Tetraphase Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.59 | 1.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.45 | 1.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.06 | 1.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.17 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.92 | 1.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.31 | 1.3% | 2 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $28.97 | 1.2% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.75 | 1.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.44 | 0.8% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $17.57 | 0.7% | 1 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $15.89 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,382.33 | 121 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $233.32 | 14 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $219.71 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $203.03 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $202.78 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $173.23 | 8 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $143.42 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $125.95 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $111.90 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $108.50 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $94.57 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $78.33 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.97 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.97 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $70.51 | 4 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $67.62 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $66.42 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $60.86 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.92 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.27 | 3 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.54 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $38.94 | 2 | 2025 |
Source payment records
|
|||||
| XERAVA Normalized: xerava |
Drug | Tetraphase Pharmaceuticals, Inc. | $35.59 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.45 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.17 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $28.97 | 1 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $28.97 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.10 | 2 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $15.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 85 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 116 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
116 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 712 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 325 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 309 | 89 |
| Metformin Hcl | Metformin Hcl | 302 | 95 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 282 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 73 |
| Losartan Potassium | Losartan Potassium | 245 | 78 |
| Pravastatin Sodium | Pravastatin Sodium | 245 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 226 | 65 |
| Famotidine | Famotidine | 222 | 52 |
| Gabapentin | Gabapentin | 214 | 52 |
| Omeprazole | Omeprazole | 210 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 54 |
| Methocarbamol | Methocarbamol | 206 | 57 |
| Clonazepam | Clonazepam | 203 | 46 |
| Alendronate Sodium | Alendronate Sodium | 202 | 60 |
| Ezetimibe | Ezetimibe | 188 | 63 |
| Lisinopril | Lisinopril | 187 | 64 |
| Alprazolam | Alprazolam | 165 | 39 |
| Varenicline Tartrate | Varenicline Tartrate | 162 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 46 |
| Naproxen | Naproxen | 149 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 32 |
| Lorazepam | Lorazepam | 125 | 29 |
| Finasteride | Finasteride | 123 | 32 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 119 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 34 |
| Mounjaro | Tirzepatide | 116 | 24 |
| Trazodone Hcl | Trazodone Hcl | 112 | 27 |
| Simvastatin | Simvastatin | 107 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 33 |
| Pregabalin | Pregabalin | 101 | 24 |
| Potassium Chloride | Potassium Chloride | 97 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 34 |
| Clobetasol Propionate | Clobetasol Propionate | 95 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 32 |
| Tramadol Hcl | Tramadol Hcl | 95 | 27 |
| Furosemide | Furosemide | 94 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 94 | 32 |
| Meclizine Hcl | Meclizine Hcl | 93 | 23 |
| Bupropion Xl | Bupropion Hcl | 90 | 27 |
| Diazepam | Diazepam | 86 | 17 |
| Metformin Hcl Er | Metformin Hcl | 86 | 24 |
| Eliquis | Apixaban | 85 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 57 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 82 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 28 |
| Mirtazapine | Mirtazapine | 82 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 24 |
| Memantine Hcl | Memantine Hcl | 81 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 24 |
| Montelukast Sodium | Montelukast Sodium | 79 | 22 |
| Buspirone Hcl | Buspirone Hcl | 72 | 18 |
| Carvedilol | Carvedilol | 72 | 17 |
| Trulicity | Dulaglutide | 70 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 14 |
| Meloxicam | Meloxicam | 68 | 20 |
| Spironolactone | Spironolactone | 67 | 21 |
| Allopurinol | Allopurinol | 66 | 23 |
| Ibuprofen | Ibuprofen | 65 | 24 |
| Baclofen | Baclofen | 62 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 20 |
| Glipizide | Glipizide | 62 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | 12 |
| Lidocaine | Lidocaine | 59 | 13 |
| Ozempic | Semaglutide | 59 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 33 |
| Atenolol | Atenolol | 57 | 18 |
| Bumetanide | Bumetanide | 57 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 16 |
| Jardiance | Empagliflozin | 52 | 19 |
| Azithromycin | Azithromycin | 51 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 17 |
| Ramipril | Ramipril | 48 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | 13 |
| Fenofibrate | Fenofibrate | 45 | 15 |
| Nystatin | Nystatin | 44 | 18 |
| Rivastigmine | Rivastigmine Tartrate | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 11 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Prednisone | Prednisone | 43 | 14 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 41 | 19 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | 20 |
| Rybelsus | Semaglutide | 39 | suppressed |
| Topiramate | Topiramate | 39 | 11 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 38 | suppressed |
| Rivastigmine | Rivastigmine | 38 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Amoxicillin | Amoxicillin | 36 | 28 |
| Sucralfate | Sucralfate | 36 | 11 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | 11 |
| Ondansetron Odt | Ondansetron | 34 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 13 |
| Prolia | Denosumab | 32 | 19 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 16 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Clozapine | Clozapine | 26 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 15 |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Nateglinide | Nateglinide | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Ergotamine-Caffeine | Ergotamine Tartrate/Caffeine | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 22 | 17 |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Permethrin | Permethrin | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 14 |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Metronidazole | Metronidazole | 14 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Cosentyx (2 Syringes) | Secukinumab | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Cefprozil | Cefprozil | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,382.33 · 121 records | ABBVIE INC. | AIRSUPRA, ARISTADA, Auvelity, CAPLYTA, CREON, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, Fetroja, GIVLAARI, INSPIRE, JARDIANCE, KISUNLA, Kimyrsa, LEQVIO, LINZESS, LYBALVI, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, Natroba, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rezzayo, Rybelsus, SUBLOCADE, Spinosad, TRELEGY ELLIPTA, UBRELVY, VOWST, VRAYLAR, Veozah, Wegovy, XERAVA, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZEVTERA | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error